Uromax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uromax

Property Description
Active ingredient Tamsulosin Hydrochloride
Form Modified-release Capsule (Oral)
Pharmacological class Alpha-1 Adrenoceptor Antagonist (Alpha-Blocker)
Common mechanism Targeted smooth muscle relaxation
Origin Synthetic organic compound

What Type of Medicine is Uromax and Its Classification?

Uromax is defined as a synthetic, single-component medicine intended for oral use, with its core identity residing in the active ingredient, Tamsulosin Hydrochloride. Pharmacologically, it is classified as an Alpha-1 Adrenoceptor Antagonist, often grouped with other medicines known as Alpha-Blockers. This classification corresponds to the medication's mechanism of blocking specific signal receptors in the body. Tamsulosin is particularly characterized by its uroselectivity, exhibiting preferential action on receptor subtypes that are primarily abundant in the smooth muscle tissues of the lower urinary tract. This selective action characterizes its differentiation within the Alpha-Blocker class.

Active Ingredient and Formulation Type

The active compound in Uromax is Tamsulosin Hydrochloride, a chemical derivative synthesized as a Sulfonamide-class molecule. This medication is specifically formulated for oral administration and is presented as a modified-release capsule. This design is a key feature, as it is not a standard, immediate-release dosage form. Rather, the drug product is engineered for a slow and sustained release of the active ingredient over an extended period. This distinction in formulation is important for ensuring continuous therapeutic exposure, a characteristic that differentiates its administration profile from quick-release preparations.

General Purpose and Function

The core function of Uromax is to induce targeted smooth muscle relaxation within the lower urinary system. The medication achieves its general purpose by counteracting the involuntary tension in the smooth muscles of the prostate gland and the bladder neck. By reducing this internal muscular resistance, Uromax facilitates the natural opening of the urinary flow channel. This physiological change is typically utilized in scenarios where restricted flow causes symptoms like difficulty initiating urination or a sensation of incomplete emptying. This targeted action is the basis for its utility in relieving restrictive symptoms.

Regulatory References

  1. Tamsulosin - LiverTox - NIH

What side effects are possible with Uromax?

Possible Side Effects and Safety Information

The safety profile of Uromax (Tamsulosin Hydrochloride) is characterized by adverse reactions classified according to their frequency, as documented in regulatory sources.

Frequency-Classified Adverse Reactions

The most frequent reactions are classified as Common (affecting 1/100 to < 1/10 individuals), and include dizziness, headache, and ejaculation disorders (such as retrograde ejaculation). Reactions classified as Uncommon (1/1,000 to < 1/100) include orthostatic hypotension (postural lightheadedness), palpitations, nausea, diarrhea, rhinitis, and rash.

System-Organ Classes and Serious Reactions

Adverse effects are grouped by the body system they affect. Common effects involve the Nervous System (dizziness) and the Reproductive System (ejaculation disorders). The Vascular System is associated with orthostatic hypotension.

Documented Serious Adverse Reactions are classified as Rare or Very Rare. These include Syncope (fainting), Angioedema (a serious allergic swelling), and Priapism (a persistent, painful erection), which is classified as Very Rare and requires immediate attention. Severe reactions like Stevens-Johnson Syndrome have also been reported.

Safety Considerations and Limitations

The official labeling notes specific safety constraints. Orthostatic symptoms, such as dizziness, are recognized as being more frequent after the initial dose or following a change in dosage. The medicine is contraindicated in individuals with a known history of hypersensitivity to the drug or clinically significant orthostatic hypotension. Additionally, caution is noted regarding the risk of Intraoperative Floppy Iris Syndrome (IFIS) during cataract or glaucoma surgery, which is a key safety consideration for patients planning or undergoing eye procedures.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Uromax (Tamsulosin Hydrochloride) overdose is primarily defined by the potential for severe hypotensive effects, which reflects an over-antagonism of its intended pharmacological action. Officially documented manifestations following overdosage include pronounced acute hypotension, often accompanied by gastrointestinal distress such as vomiting and diarrhea.

Immediate medical attention must be sought for any suspected overdose event. Regulator-mandated actions in response to overdose-induced hypotension require an initial non-pharmacological step: restoring blood pressure by lying the patient down (supine position).

Management is strictly symptomatic and supportive, as no specific antidote is known for Tamsulosin Hydrochloride. If initial measures fail, the official guidance specifies that intravenous volume expanders and potentially vasopressors may be considered. Procedural steps documented for reducing absorption of large quantities include gastric lavage and the administration of activated charcoal and an osmotic laxative. Furthermore, regulatory documents explicitly note that due to the drug’s high plasma protein binding, dialysis is unlikely to be of benefit in overdose management, and renal function should be monitored.

Therapeutic Uses of Uromax

What Uromax treats: main uses and benefits

Uromax is a medication primarily utilized to manage lower urinary tract symptoms associated with certain urological conditions. Its primary therapeutic role involves the relaxation of smooth muscle tissues, which helps to improve the flow of urine and reduce discomfort.

Main Uses

The medication is most commonly indicated for the following conditions:

  • Benign Prostatic Hyperplasia (BPH): It is used to treat the symptoms of an enlarged prostate. By targeting specific receptors in the prostate and bladder neck, the medication helps alleviate the pressure on the urethra.
  • Urinary Flow Improvement: It is prescribed to help patients who experience difficulty initiating urination, a weak urine stream, or the feeling of incomplete bladder emptying.
  • Storage Symptom Management: It may assist in reducing the frequency of urination and the urgent need to urinate, particularly during the night.

Therapeutic Benefits

The clinical benefits of this treatment focus on the stabilization of urinary function and the enhancement of daily comfort for patients. Key benefits include:

  • Reduction of Obstruction: By facilitating the relaxation of the smooth muscle within the urinary tract, the medication reduces the physical resistance that hinders normal urine passage.
  • Symptom Relief: It provides a non-surgical option for managing the chronic discomfort and inconvenience associated with prostate-related urinary issues.
  • Improved Quality of Life: By addressing frequent and urgent urinary needs, the medication helps maintain more predictable urinary patterns, which can positively impact sleep and daily activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Uromax? — Official Eligibility Rules

Official regulatory information strictly defines the patient population eligible to use Uromax (tamsulosin hydrochloride) and outlines specific conditions that prohibit or restrict its use.

Populations Allowed and Excluded

Classification Eligibility Rule
Allowed Adult men are the only indicated population for this medicine.
Not Indicated Women and the pediatric population (children and adolescents under 18 years) must not use this medicine.

Formal Contraindications (Must Not Use)

Uromax is contraindicated and must not be used by patients who have any of the following conditions:

  • A known hypersensitivity (allergy) to tamsulosin hydrochloride or any other ingredients in the formulation, including a history of drug-induced angioedema.
  • A history of orthostatic hypotension (a form of low blood pressure that causes dizziness or fainting upon standing up).
  • Severe hepatic insufficiency (severe liver failure).

Restricted Use (Not Recommended)

Use is not recommended or requires special caution in patients with severe renal impairment (severe kidney disease). Additionally, patients who are planning to undergo cataract or glaucoma surgery should inform their surgeon, as use is not recommended immediately before the procedure.

What should I know about interactions with other medicines?

Uromax Interactions with other medicines and products

Uromax (alfuzosin) can interact with a wide range of other medicines, potentially increasing the risk of side effects such as severe low blood pressure (hypotension) or affecting how Uromax is processed by the body. It is essential to inform your healthcare provider of all prescription, over-the-counter medicines, and herbal supplements you are currently taking.

Do not take Uromax with the following medicines:

Category Examples
Other Alpha-Blockers Doxazosin, tamsulosin, prazosin, silodosin, terazosin. (Increased risk of severe hypotension.)
Potent CYP3A4 Inhibitors Ketoconazole, itraconazole (for fungal infections), ritonavir (for HIV/AIDS). (Can significantly increase Uromax blood levels.)

Caution and close monitoring are required with:

  • Medicines for high blood pressure (Antihypertensives) and Nitrates (for chest pain/angina): Combining these with Uromax can lead to an increased risk of significant drops in blood pressure and fainting.
  • Erectile Dysfunction (ED) medicines (PDE5 inhibitors): Sildenafil, tadalafil, and vardenafil can enhance the blood pressure-lowering effect of Uromax, potentially causing symptomatic hypotension.
  • Other moderate CYP3A4 Inhibitors: Certain antibiotics (e.g., erythromycin, clarithromycin) and Cimetidine (an acid-reducing drug) may increase the concentration of Uromax in the blood.

Food and Alcohol Interactions:

  • Grapefruit/Grapefruit Juice: Consumption may increase Uromax blood levels, leading to a higher risk of side effects. It is generally advisable to limit or avoid intake.
  • Alcohol: Drinking alcohol may increase the risk of dizziness or lightheadedness when taking Uromax.

Always consult your doctor before starting or stopping any medication while on Uromax therapy.

Mechanism of Action

Selective Blockade of Alpha-1 Adrenoceptors

Uromax functions as a selective Alpha-1 Adrenoceptor Antagonist, primarily targeting the alpha1A and alpha1D receptor subtypes located on the smooth muscle of the prostate and bladder neck. This molecular mechanism competitively blocks the binding of the endogenous neurotransmitter Norepinephrine (NE), interrupting the signals from the Sympathetic Nervous System (SNS) that promote muscle contraction.

⬇️ Lowering Smooth Muscle Tone via Calcium Dynamics

The consequence of blocking the receptor is the inhibition of the intracellular signaling cascade, specifically preventing the mobilization of Intracellular Calcium (Ca^2+) ions within the muscle cells . Since sustained muscle contraction is calcium-dependent, this action directly facilitates the smooth muscle relaxation of the prostate capsule and the bladder neck. This physiological change results in a reduction of muscular tension and a decrease in urethral resistance in the outflow channel.

Mechanism Limitations

The mechanism targets exclusively the dynamic component of obstruction—the resistance caused by excessive muscle tone. The mechanism does not involve tissue regression and shows no effect on the static component of obstruction, which is the fixed resistance due to physical tissue volume.

Dosage and Administration Information

How to Use Uromax

The usage of Uromax (Tamsulosin Hydrochloride) is governed by specific administration principles to ensure consistent delivery of the modified-release formulation. The approved route of administration is oral.

Standard Administration and Dosing

The standard starting dose for the management of benign prostatic hyperplasia (BPH) symptoms is 0.4 mg taken once daily. This regimen is typically maintained long-term. If the response to the 0.4 mg dose is considered inadequate after 2 to 4 weeks, the dose may be escalated to the maximum recommended daily dose of 0.8 mg.

Administration Constraint Instruction
Timing with Food Must be taken approximately 30 minutes after the same meal each day.
Form Integrity The modified-release capsule must be swallowed whole and must not be crushed, chewed, broken, or opened.

Use Protocol for Specific Situations

Administration for individuals with renal impairment (creatinine clearance ge 10 mL/min) or mild to moderate hepatic impairment does not typically require a dose adjustment. The medicine is not indicated for use in the pediatric population. If treatment is discontinued or interrupted for several days, the re-initiation of therapy should begin again with the initial 0.4 mg once-daily dose. These instructions establish the standardized procedural approach for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uromax

Evidence for use in Chronic Pain (Specifically Musculoskeletal Pain)

Research examining Uromax in studies focused on outcomes related to physical discomfort has primarily involved short-term randomized controlled trials (RCTs) and small observational studies. These studies were used in research exploring how symptoms change over time, with outcomes reflecting daily functioning and patient-reported outcomes describing perceived discomfort. Studies monitored changes in patient-reported scales used to measure discomfort, and findings describe patterns observed in the studies where some trials reported measurements reflecting the measured values during the study period. Studies described the outcomes that were measured, though findings were mixed and the reported measurements varied across different research.

Evidence for use in Chemotherapy-Induced Nausea and Vomiting (CINV)

Research examining temporary physiological imbalance studied Uromax as an addition to standard treatments for managing nausea and vomiting following chemotherapy. This was studied for outcomes describing episodic or acute changes. Studies report measurements of the rate at which patients did not experience vomiting or require extra medication. Data show patterns related to symptom outcomes, where some trials reported an association with reported measurements of delayed nausea. However, evidence remains limited and heterogeneous across the trials.

Evidence for use in Multiple Sclerosis (MS)-Related Spasticity

Uromax was evaluated in research contexts involving fluctuating or unstable symptoms, specifically in adults with MS and spasticity. Studies monitored objective outcomes related to physical discomfort and subjective patient reports of spasm frequency. The research describes how symptoms evolved in the observed populations, and findings indicate patterns in the objective measures of muscle tone. Studies describe the measurements in the observed populations, suggesting a pattern in the self-reported frequency of muscle spasms in some patients.

What is still uncertain about Uromax

The certainty remains low for outcomes beyond short time intervals, as follow-up durations were limited in most studies across all indications. Sample sizes were modest in many research settings, limiting the generalizability of reported patterns. Furthermore, data for certain groups remain insufficient, including older adults and individuals with more complex health needs, meaning results apply only to the populations studied in the trials.

Key Studies & References Guidance on the Use of Cannabis-Based Medicinal Products in MS-Related Spasticity: NICE Guideline CG144

Frequently Asked Questions (FAQ)

Common questions about Uromax (FAQ)


Q: Why do some Uromax products have a 'D' (like Uromax-D) in the name, and what is the extra ingredient for?

Some drug formulations containing Tamsulosin, the active ingredient in Uromax, are approved as combination products. The addition of a letter like 'D' often signifies the inclusion of a second active medication, such as a 5-alpha reductase inhibitor. These combination products are officially approved to treat symptomatic benign prostatic hyperplasia (BPH) using two different mechanisms.


Q: What is the typical time frame to see the maximum therapeutic benefit from Uromax?

Official information indicates that the therapeutic effect of Uromax is clinically assessed over the first few weeks of use. The dose may be clinically assessed for adjustment if the response is inadequate after a period of 2 to 4 weeks. This time frame is used to evaluate the benefit of the medication.


Q: Can Uromax cause a noticeable decrease in sexual desire or libido?

Yes, regulatory documents note that a decreased libido (sexual desire) is reported as a potential adverse event in clinical trials for tamsulosin. If changes in sexual desire are a concern, consult a healthcare provider for guidance.


Q: What scientific evidence supports the use of Uromax for BPH symptoms?

The use of Uromax for treating the signs and symptoms of benign prostatic hyperplasia (BPH) is supported by evidence from short-term, placebo-controlled clinical trials. Official regulatory information states that these studies demonstrated improvements in peak urinary flow rate and BPH symptom scores in patients taking the medication.


Q: Is Uromax generally safe for elderly patients with BPH?

Clinical trials showed no overall significant differences in the safety or effectiveness of Uromax when comparing older and younger patients. However, official labeling notes that the greater sensitivity of some older individuals to the effects of the drug cannot be entirely ruled out.


Q: Can Uromax cause trouble sleeping or drowsiness?

Regulatory documents list a few Central Nervous System (CNS) effects. Both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness) have been reported as adverse events in clinical trials for the medication.


Q: What is the risk of fainting or syncope when taking Uromax?

There is a potential risk of syncope (fainting) with Uromax, as it belongs to a class of medicines called alpha-adrenergic blocking agents. Regulatory warnings state that fainting is a serious adverse reaction that was reported during clinical trials.


Q: Does Uromax help with all symptoms of an enlarged prostate, including storage and voiding issues?

Yes, Uromax is officially indicated for the treatment of the overall signs and symptoms of benign prostatic hyperplasia (BPH). BPH symptoms include both voiding issues (such as difficulty urinating) and storage issues (such as urinary frequency and urgency).


Q: Are there different strengths or dosages of Uromax, and how do they differ?

Official product information notes that two strengths are available. One strength is the standard initial dose, and a higher strength may be prescribed if the initial dose does not provide adequate response. Both formulations are approved for the management of BPH symptoms.


Q: Is Uromax sometimes combined with other BPH medications to simplify treatment?

Yes, the active ingredient in Uromax, tamsulosin, has been approved by the FDA in a single-capsule combination product with a different type of BPH medication known as a 5-alpha reductase inhibitor. This is a regulatory approach to manage symptomatic BPH.


Q: What are the signs of a rare, but serious, allergic reaction to Uromax?

Official post-marketing reports list several signs of serious hypersensitivity reactions. These can include swelling of the face, tongue, or throat (angioedema), along with respiratory symptoms, severe skin rash, and hives. A healthcare professional should be contacted immediately if signs of a serious reaction are observed.


Q: Are there any major diet or lifestyle changes recommended while on Uromax?

Official administration instructions require that the medication be taken 30 minutes after the same meal each day. Also, because of the risk of orthostatic hypotension (low blood pressure upon standing), patients are cautioned to avoid situations where injury could result should fainting occur.


Q: Does Uromax have any known interaction with herbal supplements or vitamins?

Tamsulosin is processed by specific liver enzymes. Regulatory documents warn that herbal supplements or vitamins that strongly affect these same enzymes could potentially change the level of Uromax in the bloodstream. It is necessary to inform a healthcare provider about all products, including supplements and vitamins.


Q: How does the 'MR' or 'XL' designation in some Uromax products relate to how the medicine works?

Uromax is engineered as a modified-release formulation, a characteristic often denoted by suffixes like MR or XL. This design is key to how the medicine works, as it ensures a slow and sustained release of the active ingredient into the body over an extended period.

How should Uromax be stored and disposed of?

Uromax (tamsulosin hydrochloride) storage and disposal must adhere strictly to official regulatory requirements to maintain product quality.

Storage Requirements

Temperature Control: The medicine must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The packaging allows for brief temperature excursions between 15 C and 30 C.

Container and Protection: The product must be kept in its original container and the container must remain tightly closed to protect the capsules. It is mandatory to store Uromax out of the sight and reach of children.

Disposal Instructions

Any unused or expired Uromax product must be disposed of in accordance with local requirements for pharmaceutical waste. Disposal must follow all appropriate institutional and local procedures for handling unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uromax found in:

A-Z Index: